Any feedback?
Literature summary extracted from
- Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice (2011), PLoS ONE, 6, e14644.
Application
| EC Number | Application | Comment | Organism |
|---|---|---|---|
| 3.4.24.36 | medicine | DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani inducing immune responses and conferred protection against challenge infection, humural responses, quantitative overview | Leishmania donovani |
Cloned(Commentary)
| EC Number | Cloned (Comment) | Organism |
|---|---|---|
| 3.4.24.36 | construction of full-length gp63 gene in mammalian pcDNA3.1 (2/2) expression vector, expression in CHO cells and of His-tagged protein in Escherichia coli BL21 (DE3) pLysS | Leishmania donovani |
Organism
| EC Number | Organism | UniProt | Comment | Textmining |
|---|---|---|---|---|
| 3.4.24.36 | Leishmania donovani | C7EX18 | - |
- |
Purification (Commentary)
| EC Number | Purification (Comment) | Organism |
|---|---|---|
| 3.4.24.36 | recombinant His-tagged full-length gp63 from Escherichia coli BL21 (DE3) by nickel affinity chromatography | Leishmania donovani |
Synonyms
| EC Number | Synonyms | Comment | Organism |
|---|---|---|---|
| 3.4.24.36 | Glycoprotein gp63 | - |
Leishmania donovani |
| 3.4.24.36 | gp63 | - |
Leishmania donovani |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
